← The Wire
DFTXNasdaq
Definium Therapeutics, Inc.
Medicinal Chemicals & Botanical Products · A1 · CIK 1813814
Developing novel psychedelic-derived product candidates to treat brain health disorders like anxiety and depression
red 8-K · 90d🔥 High media attention
$2.70B
Market cap
$46.55
Last close
+3.6%
1D
+26.9%
5D
4.7M
Volume
Price · last 39 sessions+114.0%
May 4L $20.02 · H $46.55Jun 29
190
Total filings
Jun 24, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · Company UpdateJun 24, 2026424B5424B5Jun 24, 2026424B5424B5Jun 22, 20268-KReg FD Disclosure · Company UpdateJun 22, 20268-KExecutive Change · Shareholder VoteJun 12, 20268-KCompany UpdateMay 19, 20268-KCompany UpdateMay 12, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 27, 2026DEF 14ADEF 14AApr 27, 20268-KCompany UpdateApr 22, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 26, 20268-KExecutive ChangeJan 29, 20268-KResults of Operations · Bylaw AmendmentJan 12, 202610-Q10-QNov 6, 20258-KResults of Operations · Company UpdateNov 6, 20258-KMaterial Agreement · Company UpdateOct 31, 2025424B5424B5Oct 31, 20258-KResults of Operations · Company UpdateOct 29, 2025424B5424B5Oct 29, 20258-KCompany UpdateSep 4, 202510-Q10-QJul 31, 20258-KResults of Operations · Company UpdateJul 31, 20258-KExecutive Change · Shareholder VoteJun 16, 20258-KExecutive Change · Reg FD DisclosureMay 27, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 23, 2025DEF 14ADEF 14AApr 23, 20258-KMaterial Agreement · New Debt / ObligationApr 21, 20258-KCompany UpdateApr 15, 202510-K10-KMar 6, 20258-KResults of OperationsMar 6, 20258-KCompany UpdateJan 30, 20258-KExecutive Change · Company UpdateJan 13, 20258-KCompany UpdateDec 16, 2024SC 13GSC 13GNov 8, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 2024SC 13GSC 13GOct 22, 20248-KMaterial Agreement · Equity IssuanceOct 17, 202410-Q10-QAug 13, 20248-KResults of OperationsAug 13, 20248-KMaterial Agreement · Results of OperationsAug 12, 2024424B5424B5Aug 12, 2024424B5424B5Aug 9, 20248-KMaterial Agreement · Company UpdateJun 28, 20248-KCompany UpdateJun 20, 20248-KShareholder VoteJun 11, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KCompany UpdateApr 1, 2024SC 13GSC 13GMar 21, 2024SC 13GSC 13GMar 15, 20248-KMaterial Agreement · Equity IssuanceMar 11, 2024424B5424B5Mar 8, 20248-KReg FD DisclosureMar 7, 20248-KReg FD Disclosure · Company UpdateMar 7, 202410-K10-KFeb 28, 20248-KResults of OperationsFeb 28, 20248-KReg FD DisclosureJan 8, 20248-KReg FD Disclosure · Company UpdateDec 14, 202310-Q10-QNov 2, 20238-KResults of Operations · Reg FD DisclosureNov 2, 20238-K/ACompany UpdateSep 15, 20238-K/ACompany UpdateSep 15, 20238-KReg FD Disclosure · Company UpdateAug 14, 20238-KMaterial Agreement · New Debt / ObligationAug 14, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-K/AShareholder VoteJul 25, 20238-KShareholder VoteJun 27, 20238-KReg FD DisclosureJun 20, 2023DEFA14ADEFA14AJun 16, 20238-KCompany UpdateJun 16, 20238-KCompany UpdateJun 15, 2023
Insider Activity
In the 90 days to Mar 25, 2026: 3 sold $1.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Barrow RobertChief Executive Officer | Sell | 24,431 | $18.47 | $451K |
| Mar 25, 2026 | Sullivan MarkChief Legal Officer | Sell | 10,702 | $18.47 | $198K |
| Mar 25, 2026 | Karlin DanielChief Medical Officer | Sell | 8,018 | $18.47 | $148K |
| Dec 26, 2025 | Barrow RobertChief Executive Officer | Sell | 25,791 | $13.15 | $339K |
| Dec 26, 2025 | Sullivan MarkChief Legal Officer | Sell | 11,276 | $13.15 | $148K |
| Dec 26, 2025 | Karlin DanielChief Medical Officer | Sell | 5,600 | $13.15 | $74K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 2 reputable articles.
Investor's Business DailyThis Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.7d agoReutersDefinium's LSD-based depression pill delivers strong late-stage results, shares surge7d agoReutersTrump's psychedelic drug order boosts investor interest with promise of faster reviews1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance